File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Asian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia

TitleAsian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia
Authors
KeywordsAdvanced stage
Diagnosis
Epidemiology
Hepatocellular carcinoma
Intermediate stage
Outcome
Staging system
Survival
Treatment
Issue Date2011
PublisherS Karger AG. The Journal's web site is located at http://www.karger.com/OCL
Citation
Oncology, 2011, v. 81 SUPPL. 1, p. 158-164 How to Cite?
AbstractHepatocellular carcinoma (HCC) is a highly prevalent disease in many Asian countries, accounting for 80% of victims worldwide. Screening programs improve the detection of early HCC and have a positive impact on survival, but the majority of HCC patients in Asia still present with advanced stage disease. The treatment outcomes of HCC are affected by multiple variables, including liver function, performance status of the patient, and tumor stage. Therefore, it is not easy to apply a multidisciplinary therapeutic approach for optimal management. At present, limited numbers of HCC patients are eligible for curative therapies such as surgery or ablation in Asia. Therefore, most patients are eligible for only palliative treatments. For optimal management, the treatment choice is guided by staging systems and treatment guidelines. Numerous staging systems have been proposed and treatment guidelines vary by region. According to the Barcelona Clinic Liver Cancer (BCLC) guideline based on evidence from randomized clinical trials, only transarterial chemoembolization (TACE) is recommended for intermediate stage HCC and sorafenib for advanced stage HCC. However, treatment guidelines from Asian countries have adopted several other therapeutic modalities such as a surgical approach, hepatic arterial infusion chemotherapy, external radiation, and their combinations based on clinical experiences for intermediate and advanced stage HCC. Although TACE is the main therapeutic modality in the intermediate stage, overall therapeutic outcomes depend on the tumor size. In the advanced stage, the prognosis depends on the tumor status, e.g. major vessel invasion or extrahepatic spread. Thus, a new staging system representing prognoses suitable for Asian HCC patients and a corresponding optimal treatment algorithm should be further investigated using evidence-based data, which will finally bring about an Asian consensus for the management of intermediate and advanced stage HCC. Copyright © 2011 S. Karger AG.
Persistent Identifierhttp://hdl.handle.net/10722/145954
ISSN
2015 Impact Factor: 2.152
2015 SCImago Journal Rankings: 0.920
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHan, KHen_HK
dc.contributor.authorKudo, Men_HK
dc.contributor.authorYe, SLen_HK
dc.contributor.authorChoi, JYen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorSeong, Jen_HK
dc.contributor.authorPark, JWen_HK
dc.contributor.authorIchida, Ten_HK
dc.contributor.authorChung, JWen_HK
dc.contributor.authorChow, Pen_HK
dc.contributor.authorCheng, ALen_HK
dc.date.accessioned2012-03-27T09:03:56Z-
dc.date.available2012-03-27T09:03:56Z-
dc.date.issued2011en_HK
dc.identifier.citationOncology, 2011, v. 81 SUPPL. 1, p. 158-164en_HK
dc.identifier.issn0030-2414en_HK
dc.identifier.urihttp://hdl.handle.net/10722/145954-
dc.description.abstractHepatocellular carcinoma (HCC) is a highly prevalent disease in many Asian countries, accounting for 80% of victims worldwide. Screening programs improve the detection of early HCC and have a positive impact on survival, but the majority of HCC patients in Asia still present with advanced stage disease. The treatment outcomes of HCC are affected by multiple variables, including liver function, performance status of the patient, and tumor stage. Therefore, it is not easy to apply a multidisciplinary therapeutic approach for optimal management. At present, limited numbers of HCC patients are eligible for curative therapies such as surgery or ablation in Asia. Therefore, most patients are eligible for only palliative treatments. For optimal management, the treatment choice is guided by staging systems and treatment guidelines. Numerous staging systems have been proposed and treatment guidelines vary by region. According to the Barcelona Clinic Liver Cancer (BCLC) guideline based on evidence from randomized clinical trials, only transarterial chemoembolization (TACE) is recommended for intermediate stage HCC and sorafenib for advanced stage HCC. However, treatment guidelines from Asian countries have adopted several other therapeutic modalities such as a surgical approach, hepatic arterial infusion chemotherapy, external radiation, and their combinations based on clinical experiences for intermediate and advanced stage HCC. Although TACE is the main therapeutic modality in the intermediate stage, overall therapeutic outcomes depend on the tumor size. In the advanced stage, the prognosis depends on the tumor status, e.g. major vessel invasion or extrahepatic spread. Thus, a new staging system representing prognoses suitable for Asian HCC patients and a corresponding optimal treatment algorithm should be further investigated using evidence-based data, which will finally bring about an Asian consensus for the management of intermediate and advanced stage HCC. Copyright © 2011 S. Karger AG.en_HK
dc.languageengen_US
dc.publisherS Karger AG. The Journal's web site is located at http://www.karger.com/OCLen_HK
dc.relation.ispartofOncologyen_HK
dc.rightsOncology. Copyright © S Karger AG.-
dc.subjectAdvanced stageen_HK
dc.subjectDiagnosisen_HK
dc.subjectEpidemiologyen_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectIntermediate stageen_HK
dc.subjectOutcomeen_HK
dc.subjectStaging systemen_HK
dc.subjectSurvivalen_HK
dc.subjectTreatmenten_HK
dc.subject.meshAsia - epidemiology-
dc.subject.meshCarcinoma, Hepatocellular - diagnosis - epidemiology - pathology - therapy-
dc.subject.meshChemoembolization, Therapeutic-
dc.subject.meshLiver Neoplasms - diagnosis - epidemiology - pathology - therapy-
dc.subject.meshNeoplasm Staging-
dc.titleAsian consensus workshop report: Expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asiaen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1159/000333280en_HK
dc.identifier.pmid22212951-
dc.identifier.scopuseid_2-s2.0-84855300819en_HK
dc.identifier.hkuros198965en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84855300819&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume81en_HK
dc.identifier.issueSUPPL. 1en_HK
dc.identifier.spage158en_HK
dc.identifier.epage164en_HK
dc.identifier.isiWOS:000298663700023-
dc.publisher.placeSwitzerlanden_HK
dc.identifier.scopusauthoridHan, KH=7402963689en_HK
dc.identifier.scopusauthoridKudo, M=54882182400en_HK
dc.identifier.scopusauthoridYe, SL=7202088340en_HK
dc.identifier.scopusauthoridChoi, JY=35253556900en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridSeong, J=7004963102en_HK
dc.identifier.scopusauthoridPark, JW=34974558100en_HK
dc.identifier.scopusauthoridIchida, T=7102582635en_HK
dc.identifier.scopusauthoridChung, JW=35241765300en_HK
dc.identifier.scopusauthoridChow, P=7202656968en_HK
dc.identifier.scopusauthoridCheng, AL=54790561500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats